Audentes Therapeutics, a preclinical biotech developing gene therapies for rare diseases, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Audentes Therapeutics plans to list on the Nasdaq under the symbol BOLD. BofA Merrill Lynch, Cowen & Company and Piper Jaffray acted as lead managers on the deal.
